A research team has shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus — a bacterial species widely resistant to antibiotics.
A research team has shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus — a bacterial species widely resistant to antibiotics.